Latest aldafermin data in NASH weigh on NGM shares

NGM shed $2.77 (20%) to $10.78 on Monday as investors appeared underwhelmed by Phase II data for aldafermin in NASH.

Interim 24-week data from cohort 4 of an adaptive Phase II trial showed that treatment with a

Read the full 368 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE